Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEMNASDAQ:KRRONASDAQ:OPTNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$8.61-3.8%$8.07$6.85▼$23.04$508.12M-0.04563,885 shs264,276 shsKRROKorro Bio$13.54-3.1%$14.64$10.29▼$98.00$127.15M2.45110,976 shs66,461 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$524.84M1.1226,986 shs3,000 shsVERVVerve Therapeutics$6.16-2.5%$4.73$2.86▼$9.31$549.12M1.671.97 million shs1.71 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics-0.33%+2.40%+17.45%+1.82%-58.77%KRROKorro Bio-5.99%+13.20%-10.10%-43.24%-67.19%OPTOpthea0.00%0.00%0.00%+7.23%+36.40%VERVVerve Therapeutics-1.10%+10.30%+51.92%+5.86%+13.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGEMCullinan Therapeutics1.5605 of 5 stars3.50.00.00.01.51.70.6KRROKorro Bio3.5719 of 5 stars4.63.00.00.04.00.00.6OPTOpthea0.8195 of 5 stars2.10.00.00.02.00.80.6VERVVerve Therapeutics2.3271 of 5 stars3.51.00.00.01.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 3.00Buy$30.00248.43% UpsideKRROKorro Bio 3.29Buy$102.43656.49% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideVERVVerve Therapeutics 3.00Buy$25.75318.02% UpsideCurrent Analyst Ratings BreakdownLatest KRRO, VERV, OPT, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/AKRROKorro Bio$4.82M26.38N/AN/A$21.19 per share0.64OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09VERVVerve Therapeutics$59.61M9.21N/AN/A$7.31 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$153.16M-$2.91N/AN/AN/AN/A-26.54%-25.32%8/14/2025 (Estimated)KRROKorro Bio-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%8/12/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)Latest KRRO, VERV, OPT, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A24.4624.46KRROKorro BioN/A11.2311.23OPTOptheaN/A2.942.94VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%KRROKorro Bio13.18%OPTOpthea55.95%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics7.16%KRROKorro Bio4.60%OPTOpthea3.20%VERVVerve Therapeutics19.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3059.02 million54.69 millionOptionableKRROKorro Bio709.39 million8.86 millionNo DataOPTOpthea8153.91 million148.98 millionNot OptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableKRRO, VERV, OPT, and CGEM HeadlinesRecent News About These CompaniesVerve Therapeutics (NASDAQ:VERV) Shares Gap Down - Should You Sell?June 13 at 1:03 PM | marketbeat.comWhat Makes Verve Therapeutics (VERV) a New Buy StockJune 13 at 1:01 PM | zacks.comVerve Therapeutics reports voting results from annual meetingJune 11 at 10:27 PM | investing.comBrokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $25.75June 11 at 1:05 AM | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up - What's Next?June 9, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by AnalystsJune 8, 2025 | marketbeat.comVerve Therapeutics (VERV) Just Reclaimed the 200-Day Moving AverageJune 6, 2025 | zacks.comVerve Therapeutics (NASDAQ:VERV) Trading 10.1% Higher - Time to Buy?June 5, 2025 | marketbeat.comWall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?June 5, 2025 | zacks.comPublic Employees Retirement System of Ohio Purchases 47,656 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)June 5, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comBank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Has $1.65 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Two Sigma Investments LPMay 31, 2025 | marketbeat.comNuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comHeart Disease Could Be a Goner When These New Drugs ArriveMay 29, 2025 | msn.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comExperimental drug promising to bring down bad cholesterol by up to 69% completes early stage trialMay 26, 2025 | theprint.inVerve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLCMay 25, 2025 | marketbeat.comNorthern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)May 25, 2025 | marketbeat.comWall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"May 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyKRRO, VERV, OPT, and CGEM Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$8.61 -0.34 (-3.80%) Closing price 04:00 PM EasternExtended Trading$8.65 +0.04 (+0.52%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Korro Bio NASDAQ:KRRO$13.54 -0.44 (-3.15%) Closing price 04:00 PM EasternExtended Trading$13.56 +0.02 (+0.11%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 06/12/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Verve Therapeutics NASDAQ:VERV$6.16 -0.16 (-2.53%) Closing price 04:00 PM EasternExtended Trading$6.14 -0.02 (-0.26%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
